Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05253313 | Magnetic Resonance Imaging for Better Selection of Pancreatic Cancer Patients for Surgery: A Randomized Clinical Trial(MAGIPAC) | unknown | N/A | 200 | University of AarhusOTHER | 0 | Mar 16, 2022 | clinicaltrials |
| NCT05281926 | A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients | unknown | Phase 1 | 10 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2022 |
| clinicaltrials |
| NCT05282433 | Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 45 | Zhongnan HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05277675 | Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)(RANT) | unknown | N/A | 160 | Southwest Hospital, ChinaOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05278195 | Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers(CHANCEsub) | unknown | — | 300 | Zhongda HospitalOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT04825470 | Liver Transplantation for Unresectable GIST Liver Metastases(TRANSGIST) | unknown | N/A | 50 | Hospital Universitario Virgen de la ArrixacaOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05275985 | 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma | unknown | N/A | 80 | Peking Union Medical College HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04835402 | Electroporation Potentiated Immunotherapy in Cancer(EPIC-1) | unknown | Phase 2 | 8 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05270642 | Plan for Microwave Thermal Field | unknown | N/A | 5 | Chinese PLA General HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03322280 | TACE Combined With Iodine-125 Seeds Implantation for HCC | unknown | N/A | 270 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04812808 | Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma(BAZE) | unknown | N/A | 10 | Hôpital FribourgeoisOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05247996 | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | N/A | 98 | The Central Hospital of Lishui CityOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05242237 | Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform | unknown | — | 300 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05242757 | Clinical Study of MAK Immune Cells in the Treatment of PHC | unknown | N/A | 12 | Zhongnan HospitalOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05240404 | Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma | unknown | Phase 2 | 116 | Xiangya Hospital of Central South UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05240690 | Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies | unknown | Phase 1 | 27 | Zhou FuxiangOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02009176 | Laparoscope Anatomical and Aon-anatomical Hepatectomy | unknown | N/A | 110 | Shuguo Zheng, MDOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03605706 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05118451 | A Multicenter RCT Study of 3DV Technology in the Diagnosis and Treatment of PLC | unknown | N/A | 420 | Zhujiang HospitalOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05233358 | HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure | unknown | N/A | 176 | The Central Hospital of Lishui CityOTHER | 0 | Feb 10, 2022 | clinicaltrials |
| NCT05201729 | Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer | unknown | — | 30 | Ruijin HospitalOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05213637 | Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 430 | Chinese PLA General HospitalOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT04617821 | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer | unknown | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT04233840 | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 72 | National Taiwan University HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05113290 | Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment | unknown | Phase 4 | 66 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05162898 | Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma. | unknown | N/A | 90 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 27, 2022 | clinicaltrials |
| NCT03067493 | RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial(RAMEC) | unknown | Phase 2 | 98 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05202015 | Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study(HepCaSt) | unknown | — | 150 | Charite University, Berlin, GermanyOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT02192671 | HR Versus RFA for HCC in Patients With PHT(HR-HCC/PHT) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT03988998 | Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma | unknown | Phase 3 | 100 | Guangxi Medical UniversityOTHER | 0 | Jan 18, 2022 | clinicaltrials |
| NCT05192044 | Less Than 100 Hours Hospital Stay After Pancreatico-duodenectomy, RCT | unknown | N/A | 40 | National Cancer Institute, EgyptOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03973112 | A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 123 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03978702 | Evaluation of the Impact of Pancreatectomy on Systemic Immunity(IMMUNOPANC) | unknown | N/A | 40 | Institut Paoli-CalmettesOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT04981665 | A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | unknown | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT04715321 | CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma | unknown | — | 120 | Sun Yat-sen UniversityOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05171309 | Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC | unknown | Phase 2 | 35 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05168254 | Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer | unknown | — | 50 | Ruijin HospitalOTHER | 1 | Dec 23, 2021 | clinicaltrials |
| NCT05166772 | Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 22, 2021 | clinicaltrials |
| NCT02944006 | Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Based on Incoherent Undersampling | unknown | — | 29 | Seoul National University HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT03731910 | Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE | unknown | N/A | 35 | Seoul National University HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05161143 | Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05154812 | Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio | unknown | Early Phase 1 | 108 | Beijing Ditan HospitalOTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05152498 | Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC) | unknown | Early Phase 1 | 142 | Beijing Ditan HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03338647 | SBRT or TACE for Advanced HCC | unknown | Phase 3 | 180 | University of AarhusOTHER | 1 | Dec 2, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 16, 2022source: clinicaltrials